ACC 2016
65th Annual Scientific Session & Expo. April 2 - 4, 2016. Chicago. Find here the highlights from ACC 16.
If you cannot view the articles, click here
PARTNER 2A: TAVI Not Inferior to Surgery in Intermediate Risk Patients
Transcatheter aortic valve replacement (TAVI) with the new generation balloon expandable valve is at least as good as surgery in intermediate risk patients with severe symptomatic aortic stenosis. ...
Transcatheter aortic valve replacement (TAVI) with the new generation balloon expandable valve is at least as good as surgery in intermediate risk patients with severe symptomatic aortic stenosis. ...
The SAPIEN 3 Valve Resulted Superior to Surgery in an Observational Study
The last generation of the balloon expandable valve resulted superior to surgery in intermediate riskpatients, in a registry analyzis. Patients treated with the SAPIEN 3 valve showed lower rates of ...
The last generation of the balloon expandable valve resulted superior to surgery in intermediate riskpatients, in a registry analyzis. Patients treated with the SAPIEN 3 valve showed lower rates of ...
CoreValve US Pivotal: at 3 Years, the Self-Expanding Valve Maintains Its Advantage vs. Surgery
At 3 year follow up, the CoreValve US Pivotal study on high risk elderly patients, the self-expanding valve showed a lasting benefit vs. surgery.These findings could suggest that the ...
At 3 year follow up, the CoreValve US Pivotal study on high risk elderly patients, the self-expanding valve showed a lasting benefit vs. surgery.These findings could suggest that the ...
PARTNER 1 in +90 Year Old Patients: TAVI and the Age Paradox
A new analyzis of the PARTNER 1 trial showed that patients over 90 undergoing transcatheter aortic valve replacement (TAVI) show no increase in mortality or major cardiovascular events rates, ...
A new analyzis of the PARTNER 1 trial showed that patients over 90 undergoing transcatheter aortic valve replacement (TAVI) show no increase in mortality or major cardiovascular events rates, ...
DANAMI 3: Deferred Stenting and Ischemic Postconditioning Have No Benefit in Primary PCI
Both ischemic postconditioning and deferred stenting showed no benefit in randomized studies conducted as part of the DANAMI 3 program.Both the DANAMI 3-DEFER and the DANAMI 3-iPOSTshowed slight ...
Both ischemic postconditioning and deferred stenting showed no benefit in randomized studies conducted as part of the DANAMI 3 program.Both the DANAMI 3-DEFER and the DANAMI 3-iPOSTshowed slight ...
Morphine Increases Platelet Reactivity in Infarctions
The use of morphine in patients undergoing ST elevation acute coronary syndromes is associated to higher platelet reactivity and lower thrombolysiscapacity, according to this small study. The ...
The use of morphine in patients undergoing ST elevation acute coronary syndromes is associated to higher platelet reactivity and lower thrombolysiscapacity, according to this small study. The ...
EARLY-BAMI: Metropol Showed No Reduction in Infarct Size.
EARLY-BAMI outcomes show the endovenous administration of metropol before primary PCI does not reduce infarct size.This double blind study randomized 683 STEMI patients within 12 hours of symptom ...
EARLY-BAMI outcomes show the endovenous administration of metropol before primary PCI does not reduce infarct size.This double blind study randomized 683 STEMI patients within 12 hours of symptom ...
New Meta-Analysis Shows Similar Mortality between Bivalirudin and Heparin
This meta-analyzis of contemporary studies comparing the safety and efficacy of bivalirudin vs. heparin showed no differences in mortality between the two drugs and, consistently with other studies, ...
This meta-analyzis of contemporary studies comparing the safety and efficacy of bivalirudin vs. heparin showed no differences in mortality between the two drugs and, consistently with other studies, ...
HOPE 3: Reducing LDL Improves Prognosis in Intermediate Risk Patients
In a large cohort of intermediate risk patients with no known CAD, treatment with low doses of statins in addition to an angiotensin receptor blocker and a diuretic, reduce the risk of cardiovascular ...
In a large cohort of intermediate risk patients with no known CAD, treatment with low doses of statins in addition to an angiotensin receptor blocker and a diuretic, reduce the risk of cardiovascular ...
ixCELL-DCM: Stem Cell Therapy Improves Outcomes in Patients with Heart Failure
Enhanced autologous bone marrow stem cell therapy improves clinical cardiac events in patients with heart failure and reduced ejection fraction resulting from ischemic heart disease and dilated ...
Enhanced autologous bone marrow stem cell therapy improves clinical cardiac events in patients with heart failure and reduced ejection fraction resulting from ischemic heart disease and dilated ...